News

Findings from this research will potentially increase the use of FA and multivitamin supplementation among women prior to pregnancy.

CAM2038 showed superiority to SL buprenorphine in trials. Braeburn recently raised $110 million in preparation for the market release of CAM2038.

During perimenopause, women are more likely to experience symptoms of depression, and during postmenopause, they are more likely to experience anxiety symptoms.

Physician burnout and stress have grown rampant across the world of medicine. What are some of the practices doctors, universities, and health care leaders use to fight them?

New research suggests hyperactivity in patients’ brain networks—known as explosive synchronization—leads to chronic pain in fibromyalgia.

The Urogynecology Director at Southside Hospital talked current and future therapies with MD Magazine.

32% of patients said they were going to stop treatment and decline further injections due to mismanaged expectations of discomfort and anxiety.

After receiving an average of 4.7 injections through year 1, patients received 0.9 injections in year 4, while maintaining gains in BCVA letters.

Engineers from the Engineering Faculty at the University of Sheffield and Boston Children’s Hospital, Harvard Medical School have created a robot with the intention of esophageal atresia .

Schistosomiasis, a chronic infection that affects more than 200 million people, is prominent in both Latin America and sub-Saharan Africa.

Arimoclomol, in development by Danish biotech Orphazyme A/S for the treatment of Niemann-Pick Disease Type C, was granted rare pediatric disease designation by the U.S. FDA this morning.

Data showed that 30-day mortality rates were significantly lower in CIU patients (18.8%) in comparison to original bed patients (34%).

Reinforcing the need for special considerations for those patients at heightened risk for CDI development is key.

More than 75% of hepatitis C patients suffer from conditions beyond the kidney. A roundtable group is trying to spread that fact.

Samples of the female genital tracts of women infected with HIV show that the virus loses much of its genetic diversity by the time it hits the bloodstream.

New research published in Annals of Internal Medicine shows that the rate of arterial and venous thrombosis was significant in patients with myeloproliferative neoplasms (MPNs).

This is the first study to compare WET directly with another PTSD treatment.

In 2018, uniQure N.V. expects to advance the clinical development of AMT-130, its investigational gene therapy for the treatment of Huntington’s disease.

The first participant has been enrolled in the American Gastroenterological Association’s (AGA) FMT study, planned to be the largest of its kind.

Last night, the U.S. FDA approved the supplemental New Drug Application to add overall survival data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for Kyprolis (carfilzomib).

Testing their system against expert manual analysis of OTC scans, the researchers determined that the automatic diagnostic method was both reliable and accurate.

Even with 250,000 overdose deaths in the past decade, federal restrictions have made treatment for opioid use disorder difficult.

An orphan drug designation request for Vitality Biopharma’s prodrug VITA-100, a cannabinoid that treats pediatric ulcerative colitis, has been sent to the U.S. FDA.

Emmaus Life Sciences has announced that Endari, a medication developed to reduce acute complications in patients with sickle cell disease, is now available by prescription in the United States.

In this Rare Connections program, Martha Raymond; Founder of the Raymond Foundation, Executive Director of Michael’s Mission, and the Co-Chair of the GI Cancers Alliance meets with Sarah Bennett, a cholangiocarcinoma survivor to highlight the space.

This morning, Novartis was granted U.S. FDA Priority Review for the drug in patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for or relapse after autologous stem cell transplant (ASCT).

Depressed elderly patients undergoing SAVR or TAVR had a 7.3% higher rate of mortality compared to non-depressed patients.

The FDA has accepted for review supplemental Biologics License Application for Ruconest for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema, Pharming Group N.V. reported this morning.

The new technology allows surgeons to develop customized surgical plans prior to entering the OR.